Categories: CancerNews

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium

NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.

Presentation Title: Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetan
Authors: Francois-Clement Bidard, Diana Bello Roufai, Arielle J. Medford, Vijaya Tirunagaru, Robert C. Doebele, Aditya Bardia
Poster Session / Category: Session 6 / Treatment: Therapeutic Strategies – Novel Targets and Targeted Agents
Poster Number: P6-10-10
Session Date and Time: Friday, December 9, 2022; 7:00 AM CT
Location: Henry B. Gonzalez Convention Center, Hall 1

A copy of the presentation materials can be accessed by visiting the “Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Investor Contact
Dan Ferry
LifeSci Advisors
+1.617.430.7576
daniel@lifesciadvisors.com

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Staff

Recent Posts

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Experienced Healthcare Executive Brings Extensive Financial and Operational Expertise to Cutera Board of DirectorsBRISBANE, Calif.--(BUSINESS…

3 hours ago

GE HealthCare Announces Changes in Strategic Leadership and Key Segments to Better Serve Patients and Customers

Roland Rott, the current president and CEO of Ultrasound, will lead Imaging, replacing Jan Makela…

3 hours ago

Glass Lens Market size is set to grow by USD 7.36 billion from 2024-2028, Rising elderly population boost the market, Technavio

NEW YORK, June 10, 2024 /PRNewswire/ -- The global glass lens market size is estimated to grow…

3 hours ago

GT Independence Expands Senior Leadership Team

Company appoints Pearl Barnett as Chief Operating Officer; Megan Owen becomes Chief Compliance Officer STURGIS,…

3 hours ago

Anne Bink, Former FEMA Official, Joins IEM

MORRISVILLE, N.C., June 10, 2024 /PRNewswire/ -- IEM International, Inc., a global leader in emergency…

3 hours ago